167 related articles for article (PubMed ID: 38087730)
21. Recent advances and problems in primary therapy for cervical cancer in Taiwan.
Chen CA; Hsieh CY
J Formos Med Assoc; 2004 Jul; 103(7):511-8. PubMed ID: 15318272
[TBL] [Abstract][Full Text] [Related]
22. Cervical morbidity in Alsace, France: results from a regional organized cervical cancer screening program.
Baldauf JJ; Fender M; Bergeron C; Marrer E; Velten M; Pradat P; Arbyn M
Eur J Cancer Prev; 2019 Jan; 28(1):33-39. PubMed ID: 29135538
[TBL] [Abstract][Full Text] [Related]
23. Cervical cancer in Africa.
Denny L; Anorlu R
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1434-8. PubMed ID: 22806169
[TBL] [Abstract][Full Text] [Related]
24. Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France.
de Rycke Y; Tubach F; Lafourcade A; Guillo S; Dalichampt M; Dahlab A; Bresse X; Uhart M; Bergeron C; Borne H; Cancalon C; Lajoinie A; Bénard S
PLoS One; 2020; 15(2):e0228660. PubMed ID: 32053648
[TBL] [Abstract][Full Text] [Related]
25. [Integrating HPV testing for primary screening?].
Riethmuller D; Ramanah R; Pretet JL; Mougin C
J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S139-51. PubMed ID: 18191912
[TBL] [Abstract][Full Text] [Related]
26. [Ethics of organized cancer screening in France].
Moutel G; Darquy S; Jullian O; Duchange N
Sante Publique; 2019; S2(HS2):67-74. PubMed ID: 32372582
[TBL] [Abstract][Full Text] [Related]
27. [Creating favorable conditions for organized screening of cervical cancer].
Baudier F
Sante Publique; 2000 May; 12 Spec No():5-10. PubMed ID: 10989624
[No Abstract] [Full Text] [Related]
28. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.
Singh D; Vignat J; Lorenzoni V; Eslahi M; Ginsburg O; Lauby-Secretan B; Arbyn M; Basu P; Bray F; Vaccarella S
Lancet Glob Health; 2023 Feb; 11(2):e197-e206. PubMed ID: 36528031
[TBL] [Abstract][Full Text] [Related]
29. Cervical and breast cancer screening participation for women with chronic conditions in France: results from a national health survey.
Constantinou P; Dray-Spira R; Menvielle G
BMC Cancer; 2016 Mar; 16():255. PubMed ID: 27029643
[TBL] [Abstract][Full Text] [Related]
30. Monitoring and evaluation of a model demonstration project for the control of cervical cancer in Nakhon Phanom province, Thailand.
Deerasamee S; Srivatanakul P; Sriplung H; Nilvachararung S; Tansuwan U; Pitakpraiwan P; Kaewkungwal J; Singhasivanon P; Nimnakorn P; Sankaranarayanan R
Asian Pac J Cancer Prev; 2007; 8(4):547-56. PubMed ID: 18260727
[TBL] [Abstract][Full Text] [Related]
31. Global strategies for cervical cancer prevention and screening.
Pimple SA; Mishra GA
Minerva Ginecol; 2019 Aug; 71(4):313-320. PubMed ID: 30808155
[TBL] [Abstract][Full Text] [Related]
32. Cervical cancer burden and prevention activities in Europe.
Kesic V; Poljak M; Rogovskaya S
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1423-33. PubMed ID: 22956728
[TBL] [Abstract][Full Text] [Related]
33. Incitation à participer à une campagne de dépistage du cancer du col de l'utérus : expérience d'un centre de soins tertiaires au Canada.
Ruel-Laliberté J; Bernard-Genest MP; Waddell G; Desindes S
J Obstet Gynaecol Can; 2020 Jun; 42(6):734-739. PubMed ID: 32279989
[TBL] [Abstract][Full Text] [Related]
34. [Post therapeutic cervical cancer surveillance in France: Priority for examination].
Bourgin C; Estevez JP; Collinet P
Gynecol Obstet Fertil Senol; 2018 May; 46(5):503-505. PubMed ID: 29615374
[No Abstract] [Full Text] [Related]
35. [Cervical cancer: Current situation and management in Morocco].
Belglaiaa E; Mougin C
Bull Cancer; 2019 Nov; 106(11):1008-1022. PubMed ID: 31606139
[TBL] [Abstract][Full Text] [Related]
36. Modelling cervical cancer elimination using single-visit screening and treatment strategies in the context of high HIV prevalence: estimates for KwaZulu-Natal, South Africa.
Rao DW; Bayer CJ; Liu G; Chikandiwa A; Sharma M; Hathaway CL; Tan N; Mugo N; Barnabas RV
J Int AIDS Soc; 2022 Oct; 25(10):e26021. PubMed ID: 36225139
[TBL] [Abstract][Full Text] [Related]
37. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers.
Lima J; Ali Z; Banerjee S
Clin Oncol (R Coll Radiol); 2021 Sep; 33(9):608-615. PubMed ID: 34312021
[TBL] [Abstract][Full Text] [Related]
39. State of the science in cervical cancer: where we are today and where we need to go.
Dizon DS; Mackay HJ; Thomas GM; Werner TL; Kohn EC; Hess D; Rose PG; Covens AL
Cancer; 2014 Aug; 120(15):2282-8. PubMed ID: 24737608
[TBL] [Abstract][Full Text] [Related]
40. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
Mutlu L; Tymon-Rosario J; Harold J; Menderes G
Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
